The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Mechanism of action of BTK degraders and insights into NX-5948
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, describes the mechanism of action of BTK degraders, which could be used as an additional line of BTK inhibition following failure to covalent and non-covalent BTK inhibitors. Prof. Collins then goes on to highlight NX-5948, an oral BTK degrader being investigated in relapsed/refractory (R/R) B-cell malignancies (NCT05131022).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Received honoraria for speaker and advisory work from:
Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio
Received research funding from:
BMS, MSD, Pfizer, Amgen, Celgene, Beigene
